Welcome to Anagrammer Crossword Genius! Keep reading below to see if rintatolimod is an answer to any crossword puzzle or word game (Scrabble, Words With Friends etc). Scroll down to see all the info we have compiled on rintatolimod.
rintatolimod
Searching in Crosswords ...
The answer RINTATOLIMOD has 0 possible clue(s) in existing crosswords.
Searching in Word Games ...
The word RINTATOLIMOD is NOT valid in any word game. (Sorry, you cannot play RINTATOLIMOD in Scrabble, Words With Friends etc)
There are 12 letters in RINTATOLIMOD ( A1D2I1L1M3N1O1R1T1 )
To search all scrabble anagrams of RINTATOLIMOD, to go: RINTATOLIMOD
Rearrange the letters in RINTATOLIMOD and see some winning combinations
10 letters out of RINTATOLIMOD
8 letters out of RINTATOLIMOD
7 letters out of RINTATOLIMOD
6 letters out of RINTATOLIMOD
5 letters out of RINTATOLIMOD
4 letters out of RINTATOLIMOD
3 letters out of RINTATOLIMOD
Searching in Dictionaries ...
Definitions of rintatolimod in various dictionaries:
RINTATOLIMOD - Rintatolimod, sold under the tradename Ampligen, is a medication intended for treatment of chronic fatigue syndrome (CFS). There is low-strength evid...
Word Research / Anagrams and more ...
Keep reading for additional results and analysis below.
| Rintatolimod description |
|---|
| Rintatolimod, sold under the tradename Ampligen, is a medication intended for treatment of chronic fatigue syndrome (CFS). There is low-strength evidence it can diminish CFS symptoms.It is an immunomodulatory double stranded RNA drug synthesized in the 1970s and manufactured by Hemispherx Biopharma.Although Ampligen was cleared for use in Canada in 1997, and obtained orphan drug status for treatment of CFS in the European Union in 2000, it is so far without FDA approval, and therefore classed as experimental in the United States. In 2007, Hemispherx filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) to market and sell rintatolimod for the treatment of CFS, but this was rejected in December 2009, because the FDA concluded that the two RCTs "did not provide credible evidence of efficacy" and "because of clinical, statistical, clinical pharmacology, nonclinical, product quality, and facilities inspection deficiencies." The FDA requested Hemispherx conduct at least one additional controlled trial to demonstrate efficacy in treating CFS. In August 2012, Hemispherx submitted further analyses of the original clinical trial data, but did not submit additional trials for review. Four months later, a committee of the FDA voted 8-5 against approval for rintatolimod, again citing insufficient data. |